Inspirna Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Private

  • Employees
  • 34

Employees

  • Latest Deal Type
  • Series D

  • Latest Deal Amount
  • $55M

  • Investors
  • 20

Inspirna General Information

Description

Developer of novel cancer drugs designed to target key pathways in cancer progression. The company's drugs identify novel cancer targets that drive tumor growth and cancer progression using a microRNA-based target discovery platform and treat it via an oral small molecule cancer metabolism inhibitor, enabling cancer patients to get optimal cures using drugs that target using small molecules and antibodies.

Contact Information

Formerly Known As
Rgenix
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 310 East 67th Street
  • Suite 1-12
  • New York, NY 10065
  • United States
+1 (646) 000-0000

Inspirna Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Inspirna Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC (Series D) 29-Aug-2022 $55M 00000 00000 Completed Clinical Trials - Phase 1
7. Later Stage VC (Series C) 24-Feb-2021 000 000.00 00000 Completed Clinical Trials - Phase 1
6. Later Stage VC (Series C) 09-Oct-2018 0000 000.00 00000 Completed Clinical Trials - Phase 1
5. Later Stage VC (Series B) 03-Jun-2016 0000 000.00 0000 Completed Pre-Clinical Trials
4. Early Stage VC (Series A) 31-Jul-2015 000 000.00 0000 Completed Pre-Clinical Trials
3. Grant 11-Aug-2014 00000 00.00 Completed Pre-Clinical Trials
2. Seed Round 30-Sep-2013 $2.5M $2.5M 00.00 Completed Pre-Clinical Trials
1. Spin-Off 01-Jan-2010 Completed Startup
To view Inspirna’s complete valuation and funding history, request access »

Inspirna Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D 000,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series C 00,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series B 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A 13,889,841 $0.000100 8% $0.61 $0.61 1x $0.61 2.79%
Seed 5,869,618 $0.000100 8% $0.53 $0.53 1x $0.53 1.18%
To view Inspirna’s complete cap table history, request access »

Inspirna Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel cancer drugs designed to target key pathways in cancer progression. The company's drugs identify nove
Drug Discovery
New York, NY
34 As of 2024
00000
00000 0000-00-00
00000000000 00000

000000

et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ulla
0000000000000
Gaithersburg, MD
00 As of 0000
00000
00000000 00000

0000 0

amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore e
0000000000000
Santa Monica, CA
0000 As of 0000
00000
000.00 0000-00-00
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Inspirna Competitors (24)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NexImmune Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
Kite Pharma Formerly VC-backed Santa Monica, CA 0000 00000 000000&0 00000
TScan Therapeutics Formerly VC-backed Waltham, MA 000 00000 00000000 00000
JW Therapeutics Formerly VC-backed Shanghai, China 000 00000 00000000 00000
Corvus Pharmaceuticals Formerly VC-backed Burlingame, CA 00 00000 00000000 00000
You’re viewing 5 of 24 competitors. Get the full list »

Inspirna Patents

Inspirna Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022316200-A1 Compositions and methods for inhibiting creatine transport as a treatment for cancer Pending 20-Jul-2021 000000000
CA-3225305-A1 Compositions and methods for inhibiting creatine transport as a treatment for cancer Pending 20-Jul-2021 000000000
EP-4373582-A1 Compositions and methods for inhibiting creatine transport as a treatment for cancer Pending 20-Jul-2021 000000000
US-20240180912-A1 Compositions and methods for inhibiting creatine transport as a treatment for cancer Pending 20-Jul-2021 0000000000
CA-3217372-A1 Mertk peptides and uses thereof Pending 14-May-2021 C12Y207/10001
To view Inspirna’s complete patent history, request access »

Inspirna Executive Team (19)

Name Title Board Seat Contact Info
Masoud Tavazoie Ph.D Co-Founder, Advisor & Board Member
Saeed Tavazoie Ph.D Co-Founder, Chief Executive Officer & Board Member
Usman Azam MD Chief Executive Officer
Sohail Tavazoie Ph.D Co-Founder & Chairman of Scientific Advisory Board
Stephen Wald Senior Vice President of Chemistry & Pharmaceutical Sciences
You’re viewing 5 of 19 executive team members. Get the full list »

Inspirna Board Members (16)

Name Representing Role Since
Antoine Papiernik Sofinnova Partners Board Member 000 0000
David Darst Self Chief Operating Officer & Board Observer 000 0000
Dieter Weinand Self Chairman 000 0000
Eric Rowinsky MD Self Executive Chairman, President and Head of Clinical Advisory Board 000 0000
Jack Nielsen Vivo Capital Board Member 000 0000
You’re viewing 5 of 16 board members. Get the full list »

Inspirna Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Inspirna Investors (20)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Dreavent Venture Capital Minority 000 0000 000000 0
Sands Capital Growth/Expansion Minority 000 0000 000000 0
Vivo Capital Venture Capital Minority 000 0000 000000 0
Bolur Holdings Impact Investing Minority 000 0000 000000 0
EXOR Seeds Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 20 investors. Get the full list »

Inspirna FAQs

  • When was Inspirna founded?

    Inspirna was founded in 2010.

  • Who is the founder of Inspirna?

    Masoud Tavazoie Ph.D, Saeed Tavazoie Ph.D, Sohail Tavazoie Ph.D, Shahram Seyedin-Noor JD, and Shahram Seyedin-Noor JD are the founders of Inspirna.

  • Who is the CEO of Inspirna?

    Masoud Tavazoie Ph.D, Saeed Tavazoie Ph.D, and Usman Azam MD are the CEOs of Inspirna.

  • Where is Inspirna headquartered?

    Inspirna is headquartered in New York, NY.

  • What is the size of Inspirna?

    Inspirna has 34 total employees.

  • What industry is Inspirna in?

    Inspirna’s primary industry is Drug Discovery.

  • Is Inspirna a private or public company?

    Inspirna is a Private company.

  • What is the current valuation of Inspirna?

    The current valuation of Inspirna is 00000.

  • What is Inspirna’s current revenue?

    The current revenue for Inspirna is 00000.

  • How much funding has Inspirna raised over time?

    Inspirna has raised $145M.

  • Who are Inspirna’s investors?

    Dreavent, Sands Capital, Vivo Capital, Bolur Holdings, and EXOR Seeds are 5 of 20 investors who have invested in Inspirna.

  • Who are Inspirna’s competitors?

    NexImmune, Kite Pharma, TScan Therapeutics, JW Therapeutics, and Corvus Pharmaceuticals are some of the 24 competitors of Inspirna.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »